TICKERNOMICS Sign up
Last Update: 2023-12-21 02:22:37
Arix Bioscience PLC ( ARIX.LSE ) https://arixbioscience.com
1.54USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United Kingdom
1y
3y
5y
10y
Historical Returns*:
SPY
21.24%
ARIX.LSE
23.16%
SPY
29.39%
-43.83%
ARIX.LSE
SPY
105.25%
-27.18%
ARIX.LSE
SPY
198.86%
ARIX.LSE
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
194.47
66.62
0.42
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-2.74
168.66
0.64
-3.19
0.00
0.00
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
0.00
0.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
7.184
-6.96
-6.04
0.80
Other Earnings and Cash Flow Stats:
Arix Bioscience PLC ( ARIX.LSE ) Net Income TTM ($MM) is 0.00
Arix Bioscience PLC ( ARIX.LSE ) Operating Income TTM ($MM) is 0.00
Arix Bioscience PLC ( ARIX.LSE ) Owners' Earnings Annual ($MM) is -8.37
Arix Bioscience PLC ( ARIX.LSE ) Current Price to Owners' Earnings ratio is -20.44
Arix Bioscience PLC ( ARIX.LSE ) EBITDA TTM ($MM) is 0.00
Arix Bioscience PLC ( ARIX.LSE ) EBITDA Margin is 0.00%
Capital Allocation:
Arix Bioscience PLC ( ARIX.LSE ) has paid 0.00 dividends per share and bought back -0.208708 million shares in the past 12 months
Arix Bioscience PLC ( ARIX.LSE ) has increased its debt by 0.0 million USD in the last 12 months
Capital Structure:
Arix Bioscience PLC ( ARIX.LSE ) Interest-bearing Debt ($MM) as of last quarter is 0
Arix Bioscience PLC ( ARIX.LSE ) Annual Working Capital Investments ($MM) are 24
Arix Bioscience PLC ( ARIX.LSE ) Book Value ($MM) as of last quarter is 302
Arix Bioscience PLC ( ARIX.LSE ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
Arix Bioscience PLC ( ARIX.LSE ) has 127 million in cash on hand as of last quarter
Arix Bioscience PLC ( ARIX.LSE ) has 1 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Arix Bioscience PLC ( ARIX.LSE ) has 129 common shares outstanding as of last quarter
Arix Bioscience PLC ( ARIX.LSE ) has 0 million USD of preferred stock value
Academic Scores:
Arix Bioscience PLC ( ARIX.LSE ) Altman Z-Score is 66.06 as of last quarter
Arix Bioscience PLC ( ARIX.LSE ) Piotroski Score is 1.00 as of last quarter
Corporate Governance:
Arix Bioscience PLC ( ARIX.LSE ) largest shareholder is owning shares at 0.00 ($MM) value
(an insider) shares of Arix Bioscience PLC ( ARIX.LSE ) for the amount of $ on
26.14% of Arix Bioscience PLC ( ARIX.LSE ) is held by insiders, and 52.07% is held by institutions
Arix Bioscience PLC ( ARIX.LSE ) went public on 1970-01-01
Other Arix Bioscience PLC ( ARIX.LSE ) financial metrics:
FCF:-6.36
Unlevered Free Cash Flow:-62.43
EPS:0.00
Operating Margin:0.00
Gross Profit Margin:0.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:0.00
Beta:0.80
Buffet's Owners Earnings:-8.37
Price to Owner's Earnings:-20.44
About Arix Bioscience PLC ( ARIX.LSE ) :
Arix Bioscience plc is a venture capital firm specializing in all stages of growth, seed stage, preclinical and clinical stage assets, startup, early stage, mid venture, late stage, growth capital investments as well as private and public equity. The firm seeks to invest in biotech companies, novel therapeutics, innovative technologies, medical innovation comprising healthcare and life sciences. It seeks to invest globally. The firm employs an evergreen approach to funding. It primarily makes investments from its own balance sheet. The firm prefers to take board seat. The firm exit when the optimum value has been reached. Arix Bioscience plc is formerly known as Perceptive Bioscience Investments Limited. Arix Bioscience plc was founded in 2015 and is based in London, United Kingdom.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.